Camurus 
Welcome,         Profile    Billing    Logout  
 4 Products   2 Diseases  4 Products   7 Trials   152 News 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oclaiz (octreotide subcutaneous depot) / Camurus
NCT04076462 / 2019-001191-11: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Completed
3
72
Europe, US, RoW
CAM2029 (octreotide subcutaneous depot), CAM2029, Matching placebo, placebo
Camurus AB
Acromegaly
05/23
05/23
NCT04125836 / 2019-002190-66: A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Completed
3
135
Europe, US, RoW
CAM2029 (octreotide subcutaneous depot), CAM2029
Camurus AB
Acromegaly
04/25
04/25
SORENTO, NCT05050942 / 2021-000849-40: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET

Active, not recruiting
3
332
Europe, Canada, US, RoW
CAM2029, Octreotide LAR, Lanreotide ATG
Camurus AB, Camurus AB
Gastro-enteropancreatic Neuroendocrine Tumor
12/25
12/27
2021-003764-27: This study is being conducted to evaluate efficacy and safety of Octreotide compared with Placebo via subcutaneous depot route in subjects with polycystic liver disease

Not yet recruiting
2/3
69
Europe
CAM2029 (Octreotide subcutaneous depot), CAM2029, Prolonged-release solution for injection
Camurus AB, Camurus AB
Polycystic liver disease, Multiple fluid filled sac in liver, Diseases [C] - Digestive System Diseases [C06]
 
 
POSITANO, NCT05281328 / 2021-003764-27: A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Active, not recruiting
2/3
71
Europe, US
CAM2029, octreotide subcutaneous depot, Placebo
Camurus AB, Camurus AB
Polycystic Liver Disease
02/25
08/27
2021-000598-95: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders Ensayo de fase II, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de octreotida subcutánea de liberación prolongada (CAM2029) en pacientes con síndrome de dificultad respiratoria aguda (SDRA) causado por COVID-19 u otros trastornos

Not yet recruiting
2
40
Europe
Octreotide subcutaneous depot, CAM2029, Prolonged-release solution for injection
Camurus AB, Camurus AB
Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders síndrome de dificultad respiratoria aguda (SDRA) causado por COVID-19 u otros trastornos, Acute respiratory distress syndrome síndrome de dificultad respiratoria aguda, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
MOMs-CMA, NCT03911466: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

Completed
3
97
US
Buprenorphine Injection, CAM2038, Buprenorphine Sublingual Product, Subutex, Suboxone
T. John Winhusen, PhD, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
11/24
11/24
MOMs, NCT03918850: Medication Treatment for Opioid Use Disorder in Expectant Mothers

Completed
3
140
US
Buprenorphine Injection, CAM2038, Buprenorphine Sublingual Product, Subutex, Suboxone
T. John Winhusen, PhD, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
01/25
01/25
MOMs-INO, NCT03911739: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

Completed
3
71
US
Buprenorphine Injection, CAM2038, Buprenorphine Sublingual Product, Subutex, Suboxone
T. John Winhusen, PhD, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
12/24
12/24
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Active, not recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
12/26
12/26
treprostinil subcutaneous depot (CAM2043) / Camurus
2019-002444-24: Clinical trial of a single dose of treprostinil injected as a depot under the skin to investigate the effect on the digital blood flow and safety in patients with Raynaud’s Phenomenon due to Systemic Sclerosis

Not yet recruiting
2
12
Europe
CAM2043, CAM2043, Prolonged-release solution for injection
Camurus AB, Camurus AB
Raynaud’s phenomenon secondary to systemic sclerosis, Raynaud’s phenomenon due to systemic sclerosis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oclaiz (octreotide subcutaneous depot) / Camurus
NCT04076462 / 2019-001191-11: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Completed
3
72
Europe, US, RoW
CAM2029 (octreotide subcutaneous depot), CAM2029, Matching placebo, placebo
Camurus AB
Acromegaly
05/23
05/23
NCT04125836 / 2019-002190-66: A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Completed
3
135
Europe, US, RoW
CAM2029 (octreotide subcutaneous depot), CAM2029
Camurus AB
Acromegaly
04/25
04/25
SORENTO, NCT05050942 / 2021-000849-40: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET

Active, not recruiting
3
332
Europe, Canada, US, RoW
CAM2029, Octreotide LAR, Lanreotide ATG
Camurus AB, Camurus AB
Gastro-enteropancreatic Neuroendocrine Tumor
12/25
12/27
2021-003764-27: This study is being conducted to evaluate efficacy and safety of Octreotide compared with Placebo via subcutaneous depot route in subjects with polycystic liver disease

Not yet recruiting
2/3
69
Europe
CAM2029 (Octreotide subcutaneous depot), CAM2029, Prolonged-release solution for injection
Camurus AB, Camurus AB
Polycystic liver disease, Multiple fluid filled sac in liver, Diseases [C] - Digestive System Diseases [C06]
 
 
POSITANO, NCT05281328 / 2021-003764-27: A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Active, not recruiting
2/3
71
Europe, US
CAM2029, octreotide subcutaneous depot, Placebo
Camurus AB, Camurus AB
Polycystic Liver Disease
02/25
08/27
2021-000598-95: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders Ensayo de fase II, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de octreotida subcutánea de liberación prolongada (CAM2029) en pacientes con síndrome de dificultad respiratoria aguda (SDRA) causado por COVID-19 u otros trastornos

Not yet recruiting
2
40
Europe
Octreotide subcutaneous depot, CAM2029, Prolonged-release solution for injection
Camurus AB, Camurus AB
Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders síndrome de dificultad respiratoria aguda (SDRA) causado por COVID-19 u otros trastornos, Acute respiratory distress syndrome síndrome de dificultad respiratoria aguda, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
Brixadi once-monthly depot (buprenorphine once-monthly depot) / Camurus, Braeburn
MOMs-CMA, NCT03911466: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

Completed
3
97
US
Buprenorphine Injection, CAM2038, Buprenorphine Sublingual Product, Subutex, Suboxone
T. John Winhusen, PhD, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
11/24
11/24
MOMs, NCT03918850: Medication Treatment for Opioid Use Disorder in Expectant Mothers

Completed
3
140
US
Buprenorphine Injection, CAM2038, Buprenorphine Sublingual Product, Subutex, Suboxone
T. John Winhusen, PhD, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
01/25
01/25
MOMs-INO, NCT03911739: Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

Completed
3
71
US
Buprenorphine Injection, CAM2038, Buprenorphine Sublingual Product, Subutex, Suboxone
T. John Winhusen, PhD, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
12/24
12/24
NCT04464980: Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Active, not recruiting
2
2190
US
SL-BUP, sublingual buprenorphine, Suboxone, XR-BUP, extended-release buprenorphine, CAM2038, Brixadi, XR-NTX, extended-release naltrexone, Vivitrol, MM, MMR, MMD
NYU Langone Health, New York State Psychiatric Institute, Columbia University, Harvard Medical School (HMS and HSDM), Mclean Hospital, National Institute on Drug Abuse (NIDA), The Emmes Company, LLC
Opioid Use Disorder (OUD)
12/26
12/26
treprostinil subcutaneous depot (CAM2043) / Camurus
2019-002444-24: Clinical trial of a single dose of treprostinil injected as a depot under the skin to investigate the effect on the digital blood flow and safety in patients with Raynaud’s Phenomenon due to Systemic Sclerosis

Not yet recruiting
2
12
Europe
CAM2043, CAM2043, Prolonged-release solution for injection
Camurus AB, Camurus AB
Raynaud’s phenomenon secondary to systemic sclerosis, Raynaud’s phenomenon due to systemic sclerosis, Diseases [C] - Musculoskeletal Diseases [C05]
 
 

Download Options